April 20th 2024 | 1:03

News

The first innovative drug Vydura arrives to prevent and treat migraine

The first innovative drug Vydura arrives in Spain to prevent and treat migraine

Jeickson Sulbaran

February 21, 2024 | 4:26 p.m.

The arrival of Vydura in Spain marks a milestone in the fight against migraine, a neurological disease that not only affects 12% of the Spanish population., but it is also positioned as one of the ten most disabling pathologies worldwide, according to the World Health Organization (WHO). This condition, which significantly impacts the quality of life of patients, has found new hope in Vydura, especially for those who suffer between 8 and 14 attacks a month.

The impact of migraine and the need for effective solutions

The first innovative drug Vydura arrives in Spain to prevent and treat migraine

Migraine is not just a headache. It is a complex condition that brings with it debilitating pain and a series of symptoms that significantly alter the daily lives of those who suffer from it. With 54% of those affected in Spain stating that they have not yet found an effective solution to manage the effects of this disease, the arrival of Vydura represents a ray of hope.

This medication, whose active ingredient is rimegepant, is not only presented as an option for the acute treatment of migraine, but also as a preventive alternative. The European Commission authorized its use in April 2022, and recently, the Spanish Interministerial Commission on Drug Prices has approved its financing, establishing a price of 464,34 euros for each container of 16 tablets.

Criteria for financing Vydura in Spain and its availability

The public financing of Vydura, however, comes with certain limitations. As explained by José Chaves, medical director of Pfizer Spain, the drug manufacturing company., only those patients who experience between 8 and 14 migraine attacks per month, have undergone at least three previous treatments without an adequate response and have a prescription from a specialist, will be able to access reimbursement from the National Health System. This places Vydura as a viable option mainly for the most severe cases of migraine, leaving other patients the possibility of accessing the medication in pharmacies at a market price of 29 euros per tablet.

The operation of Vydura in Spain is notable. It acts on the calcitonin gene-related peptide pathway, offering fast and long-lasting relief. Studies carried out by the pharmaceutical company reveal that around 20% of patients do not feel pain two hours after its administration in acute crisis situations. Furthermore, for prevention, an average reduction of 6,2 migraine days per month was observed in each treated patient.

This advance is crucial in a context where migraine is often misunderstood and stigmatized. As Jesús Porta-Etessam, president of the Spanish Society of Neurology, points out, migraine is a disease that occurs due to crises, which leads many to minimize its impact. However, for those affected, the reality is a constant struggle with pain and the inability to perform daily activities.

The arrival of Vydura to Spain is a significant advance in the treatment and prevention of migraine. Although its funding is limited to a specific group of patients, its availability represents an important step toward improving the quality of life of those suffering from this debilitating disease.

More news